linagliptin and semaglutide together (Wegovy®) Comparative efficacy of once-weekly semaglutide

2.3 Pharmacological treatments for DPN According to the relevant guidelines in China released in 2021 ( 3 Preclinical evidence of neuroprotective effects of GLP-1R agonists in DPN In patients with DM, the metabolism of glucose, lipids, proteins, and nuclear acids is largely dysregulated

These discrepancies may be attributed to differences in pathology, treatment duration, and timing across models

H.HermansonD

NTS, nucleus tractus solitarius

injectable), patient populations (with or without T2DM), and treatment durations

Individual peptides vary based on their amino acid sequence, and some are far more sensitive than others